NIPT Ultra

Description

Designed for expecting parents seeking early insights into their baby’s chromosomal health, NIPT Ultra screens for common trisomies (21, 18, 13), sex chromosome abnormalities, and large chromosomal deletions or duplications (CNVs >7Mb), with optional gender determination. This DNA-based test uses only a maternal blood sample and is safe, non-invasive, and highly accurate—offering clarity and reassurance from as early as 10 weeks of pregnancy.

🎯 Purpose: To screen for aneuploidies and large genetic imbalances in the fetus

✅ Benefits:
• Early risk assessment for major chromosomal abnormalities
• Safe and non-invasive alternative to invasive prenatal procedures
• Enables proactive care and planning during pregnancy
• Optional gender determination included

🧪 Sample Type: Maternal blood
⚠️ Preparation: None
🗒️ Important Notes: Referral from a UAE-licensed doctor is required. Minimum gestational age must be 10 weeks. Recent ultrasound report is mandatory.
🕒 TAT: 8-10 days

📌 Disclaimer – NIPT Screening
This screening test is intended to assess the risk of specific chromosomal conditions in the fetus, including Trisomy 21 (Down syndrome), Trisomy 18, Trisomy 13, and certain sex chromosome abnormalities (XO, XXX, XXY, XYY). It is performed from 10 weeks of gestation onward and is based on analysis of cell-free fetal DNA in the mother’s blood.

The test is not designed to detect all genetic or chromosomal disorders. Conditions involving other chromosomes or structural changes may not be identified.

For twin pregnancies, the detection of chromosomal differences may be possible, but the test cannot determine which twin is affected. Fetal sex determination may also be limited in multiple pregnancies.

A high-risk (positive) result suggests a potential chromosome difference and should be followed by diagnostic testing (e.g., amniocentesis or chorionic villus sampling) to confirm.
A low-risk (negative) result reduces the likelihood of the tested conditions but does not completely eliminate the chance of abnormalities, especially in cases involving family history or abnormal ultrasound findings.

In rare situations, results may be inconclusive due to biological or technical limitations. Follow-up through ultrasound and additional screening may be necessary.

This test is not a diagnostic tool and should not replace detailed medical evaluation. Clinical decisions should be made in consultation with a qualified healthcare provider or genetic specialist.